Trial Profile
Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2010
Price :
$35
*
At a glance
- Drugs Saracatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 20 Dec 2010 New trial record